Article
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.
Leukemia - 1 Sept 2022
Schönfeld Lioba, Rinke Jenny, Hinze Anna, Nagel Saskia N, Schäfer Vivien, Schenk Thomas, Fabisch Christian, Brümmendorf Tim H, Burchert Andreas, le Coutre Philipp, Krause Stefan W, Saussele Susanne, Safizadeh Fatemeh, Pfirrmann Markus, Hochhaus Andreas, Ernst Thomas
Abstract excerpt
Gene mutations independent of BCR::ABL1 have been identified in newly diagnosed patients with chronic myeloid leukemia (CML) in chronic phase, whereby mutations in epigenetic modifier genes were most common. These findings prompted the systematic analysis of prevalence, dynamics, and prognostic significance of such mutations, in a clinically well-characterized patient population of 222 CML patients from the TIGER...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.